46 completed, 6 terminated, 3 active not recruiting, 1 not yet recruiting. 22 Phase 4, 14 Phase 3, 11 Phase 2, 5 Not applicable, 5 Phase 1.
Follow pimecrolimus: new trials by email Literature Review of pimecrolimus trials Research Report on pimecrolimus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of Vulvar Lichen Sclerosus With Corticosteroid Ointment, Calcineurin Inhibitor Ointment, and Platelet-Rich Plasma (PRP) Therapy. Platelet-Rich Plasma (PRP) Treatment, Clobetasol Propionate 0.05% Cream (Dermovate), Pimecrolimus Cream (Elidel) - Vulvar Lichen Sclerosus | Not applicable | Not yet recruiting | Milosz Pietrus | 45 | 2025-12-01 | 2025-11-20 |
| Observational Study to Evaluate Use of Elidel® in South and East Asian Pediatric Patients With Atopic Dermatitis. Elidel 1% Topical Cream - Mild to Moderate Atopic Dermatitis | Active not recruiting | BGP Products Operations GmbH, a Viatris company | 130 | 2024-10-15 | 2026-06-25 | |
| A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment Pimecrolimus 0.3% Ophthalmic Ointment, Placebo Ophthalmic Ointment - Blepharitis | Phase 3 | Terminated | Famy Life Sciences, a Viatris Company | 477 | 2024-04-22 | 2026-01-07 |
| A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor Amlitelimab, Placebo, Topical corticosteroids - Dermatitis Atopic | Phase 3 | Active not recruiting | Sanofi | 464 | 2024-02-29 | 2026-10-13 |
| A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of IN-A002 Ointment in Healthy Adult Male Volunteers and Mild to Moderate Atopic Dermatitis Patients IN-A002 Ointment 0.3% or IN-A002 Placebo Ointment, IN-A002 Ointment 0.5% or IN-A002 Placebo Ointment, IN-A002 Ointment 1% or IN-A002 Placebo Ointment - Mild to Moderate Atopic Dermatitis | Phase 1 | Completed | HK inno.N Corporation | 81 | 2023-02-13 | 2026-09-14 |
| Observational Study to Evaluate the Actual Use of Elidel® in Chinese Patients With Mild to Moderate Atopic Dermatitis Pimecrolimus 1% Top Cream - Atopic Dermatitis | Completed | Mylan Inc. | 130 | 2021-03-18 | 2023-05-24 | |
| Efficacy of Topical Pimecrolimus in the Treatment of Pityriasis Alba Elidel (pimecrolimus 1%), Cold Cream - Pityriasis Alba | Phase 2 / Phase 3 | Unknown | St Joseph University, Beirut, Lebanon | 40 | 2019-03-01 | 2019-02-11 |
| A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD Crisaborole ointment, 2%, Hydrocortisone butyrate cream, 0.1%, Pimecrolimus cream, 1% - Atopic Dermatitis | Phase 4 | Terminated | Pfizer | 237 | 2018-04-27 | 2022-01-10 |
| Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis Pimecrolimus Cream, 1%, Elidel® (pimecrolimus) Cream, Placebo of Pimecrolimus Cream, 1% - Atopic Dermatitis | Phase 3 | Completed | Glenmark Pharmaceuticals Ltd. India | 755 | 2016-08-01 | 2019-07-31 |
| Safety and Bioequivalence of Pimecrolimus Cream 1% and Elidel R in Treatment of Mild to Moderate Atopic Dermatitis pimecrolimus cream 1%, Elidel (pimecrolimus) cream 1%, placebo - Atopic Dermatitis | Phase 3 | Completed | Par Pharmaceutical, Inc. | 582 | 2016-06-01 | 2017-09-29 |
| Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic Dermatitis Pimecrolimus Cream, 1%, Placebo Cream - Atopic Dermatitis | Phase 3 | Completed | Mylan Inc. | 654 | 2016-02-29 | 2022-03-07 |
| A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD) Pimecrolimus cream, Betamethasone dipropionate cream, Clobetasol propionate cream - Atopic Dermatitis | Phase 1 | Completed | LEO Pharma | 30 | 2015-02-01 | 2025-02-24 |
| Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel® 1% in Subjects With Mild to Moderate Atopic Dermatitis Pimecrolimus Cream 1% (Valeant), Vehicle cream, Pimecrolimus Cream, 1% - Atopic Dermatitis | Phase 3 | Completed | Actavis Inc. | 587 | 2015-02-01 | 2020-05-29 |
| A Multi-Centre Clinical Trial to Evaluate a Left-Right Design in Adults With Mild to Moderate Atopic Dermatitis pimecrolimus 10 mg/g cream, Vehicle cream - Atopic Dermatitis | Phase 1 | Completed | LEO Pharma | 30 | 2014-04-01 | 2025-02-24 |
| 1% Topical Pimecrolimus Cream for the Treatment of the Rash Associated With ERBITUX Pimecrolimus, Placebo - Rash | Phase 2 | Terminated | West Virginia University | 13 | 2012-02-01 | 2017-03-15 |
| Clinical and Immunohistochemical Effect of Topical Pimecrolimus in Treatment of Oral Lichen Planus Pimecrolimus 1% cream, Betamethasone 17-valerate 0.1% cream - Oral Lichen Planus | Phase 4 | Completed | Ain Shams University | 24 | 2010-09-01 | 2015-05-13 |
| LEO 29102 Cream in the Treatment of Atopic Dermatitis LEO 29102, Elidel® - Atopic Dermatitis | Phase 2 | Completed | LEO Pharma | 183 | 2009-12-01 | 2025-03-10 |
| Effect of Pimecrolimus Cream on Cathelicidin Levels in Subjects With Eczema Pimecrolimus, Vehicle cream - Atopic Dermatitis | Not applicable | Completed | University of California, San Diego | 40 | 2009-10-01 | 2014-03-10 |
| Pimecrolimus Cream 1% (Elidel®) and Medicated Device Cream (EletoneTM) in the Treatment and Maintenance of Atopic Dermatitis. pimecrolimus, topical medical device - Atopic Dermatitis | Phase 4 | Completed | Emer, Jason, M.D. | 20 | 2009-09-01 | 2010-08-09 |
| Comparison of Skin Thickness Under Treatment With Pimecrolimus 1% Cream, Hydrocortisonacetat 1% Cream, Betamethasonvalerat 0,1% Cream and Clobetasol-17-propionat 0,05% Cream Assessed by Optical Coherence Tomography (OCT) and 20-MHZ Ultrasound pimecrolimus 1% cream, hydrocortisonacetat 1% cream, betamethasonvalerat 0,1% cream - Healthy | Phase 1 | Completed | Technische Universität Dresden | 40 | 2008-01-01 | 2014-06-11 |
Showing 20 of 58. Sign in to see all of them.
Dermatitis, Atopic (38) · Eczema (6) · Lichen Planus, Oral (3) · Dermatitis (2) · Lupus Erythematosus, Discoid (2) · Asthma (1) · Blepharitis (1) · Dandruff (1) · Dermatitis, Perioral (1) · Dermatitis, Seborrheic (1) · Dry Eye Syndromes (1) · Exanthema (1) · Facies (1) · Keratoconjunctivitis Sicca (1) · Lichen Sclerosus et Atrophicus (1)
Novartis (16) · Astellas Pharma Inc (3) · LEO Pharma (3) · Novartis Pharmaceuticals (3) · Technische Universität Dresden (3) · Children's Hospital of Philadelphia (2) · Mylan Inc. (2) · Actavis Inc. (1) · Ain Shams University (1) · BGP Products Operations GmbH, a Viatris company (1) · Bausch Health Americas, Inc. (1) · Bayer (1) · Center for Vulvovaginal Disorders (1) · Centre Hospitalier Universitaire de Nice (1) · Children's Hospital of Michigan (1)
United States (24) · Germany (16) · Canada (4) · Japan (3) · Poland (3) · Switzerland (3) · United Kingdom (3) · China (2) · Israel (2) · Italy (2) · Mexico (2) · South Korea (2) · Spain (2) · Taiwan (2) · Argentina (1)
Roland Aschoff, MD (2) · Albert C Yan, MD (1) · Andrew T Goldstein, MD (1) · Behrooz Barikbin, M.D. (1) · Bernard Goffe, MD (1) · Beth Landis (1) · Christopher Hull, MD (1) · Debra Breneman, MD (1) · Dr. Nikhil Sawant (1)
PMID 15568399, PMID 17438179, PMID 18462835, PMID 18703875, PMID 20083693, PMID 21099191, PMID 21175873, PMID 21353334, PMID 21771098, PMID 25802354, PMID 26598458
2018 (1), 2023 (1)